Marc Panoff (LBRX) Files Form 3 Showing Shares and Multi-Year Option Grants
Rhea-AI Filing Summary
Marc L. Panoff, Senior Vice President, Finance and director of LB Pharmaceuticals (LBRX), filed an Initial Statement of Beneficial Ownership reporting direct ownership of 10,242 shares of common stock and multiple employee stock options. The filing lists options exercisable between 2028 and 2034 covering 27,609 underlying shares with exercise prices ranging from $41.84 to $69.72. The form is signed and dated 09/10/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine Section 16 Form 3 disclosing officer/director ownership and outstanding options; no unusual transactions.
The filing documents direct ownership of 10,242 common shares and a portfolio of employee stock options totaling 27,609 underlying shares with staggered exercisability from 2028 to 2034 and strike prices between $41.84 and $69.72. Vesting schedules are typical: initial one-quarter vesting with remaining shares vesting monthly over 36 months, subject to continued service. This is a standard initial beneficial-ownership disclosure for an officer/director.
TL;DR: Standard Form 3 disclosure confirming officer/director equity stake and option grants; governance implications negligible.
The report confirms Marc Panoff's roles as Senior VP, Finance and director and provides transparent disclosure of direct share ownership and employee stock options. Vesting provisions and exercise prices are clearly stated, enabling assessment of potential future share dilution. There are no indications of immediate exercises, sales, or related-party transactions in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Immediately exercisable. One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
